Report: Injectable antibodies top growth chart

10/11/2007 | NYTimes.com

Sales of injectable monoclonal antibodies will grow 14% annually from 2006 to 2012, preserving their status as the fastest-growing class of drugs during the next five years, market analyst Datamonitor says in its latest report. Antibody-based drugs already are popular for the treatment of cancer and rheumatoid arthritis and currently generate $20 billion in global revenue.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Actuary
NTA Life
Addison, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA